Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  ImmunoGen, Inc.    IMGN   US45253H1014

IMMUNOGEN, INC. (IMGN)

15
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period June 201220132014201520162017
Sales16,435,559,9100107121
Operating income (EBITDA)--68,4-66,9-52,7-42,0-22,5
Operating profit (EBIT)-73,3-73,0-71,5-58,6-63,4-50,1
Pre-Tax Profit (EBT)-73,3-72,8----
Net income-73,3-72,8-71,4-59,0-66,0-51,4
EPS ( $)-0,95-0,87-0,83-0,69-0,70-0,48
Dividend per Share ( $)------
Yield------
Announcement Date08/03/2012
10:30am
08/02/2013
10:30am
08/01/2014
10:30am
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period June 201220132014201520162017
Debt------
Finance-19514279,692,748,3
Operating income (EBITDA)--68,4-66,9-52,7-42,0-22,5
Leverage
(Debt/EBITDA)
------
Capital Expenditure2,903,778,186,026,251,50
Book Value Per Share (BVPS)-1,44 $0,88 $0,41 $1,52 $0,12 $
Cash Flow per Share--0,72 $-0,63 $-0,67 $-0,33 $-
Announcement Date08/03/2012
10:30am
08/02/2013
10:30am
08/01/2014
10:30am
---
Assessed data source :
© 2014 Thomson Reuters
Advertisement
Financial Ratios

Size 2015e 2016e
Capitalization 525 M$ -
Entreprise Value (EV) 445 M$ 432 M$
Valuation 2015e 2016e
PER (Price / EPS)
Capitalization / Revenue 5,23x 4,89x
EV / Revenue 4,44x 4,02x
EV / EBITDA -8,45x -10,3x
Yield (DPS / Price) - -
Profitability 2015e 2016e
Operating Margin (EBIT / Sales) -58,4% -59,0%
operating Leverage (Delta EBIT / Delta Sales) 0,27x -
Net Margin (Net Profit / Revenue) -58,7% -61,4%
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) -109% -171%
Rate of Dividend - -
Balance Sheet Analysis 2015e 2016e
CAPEX / Sales   5,99% 5,82%
Cash Flow / Sales (Taux d'autofinancement) -57,1% -26,4%
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) 1,51x 2,20x
EPS & Dividend
Dynamic quotes  
ON
| OFF